The macrophage: a therapeutic target in HIV-1 infection

  • Amit Kumar
  • Georges Herbein
Keywords: HIV-1, Macrophages, Nef, Tat, Vpr, Antiretroviral therapy, Latency

Abstract

Human immunodeficiency virus (HIV) is still a serious global health concern responsible for more than 25 million
deaths in last three decades. More than 34 million people are living with HIV infection. Macrophages and CD4+
T cells are the principal targets of HIV-1. The pathogenesis of HIV-1 takes different routes in macrophages and CD4+
T cells. Macrophages are resistant to the cytopathic effect of HIV-1 and produce virus for longer periods of time.
In addition, macrophages being present in every organ system thus can disseminate virus to the different anatomical
sites leading to the formation of viral sanctuaries. Complete cure of HIV-1 needs better understanding of viral
pathogenesis in these reservoirs and implementation of knowledge into robust therapeutic products. In this review
we will focus on the unique relationship between HIV-1 and macrophages. Furthermore, we will describe how
successful antiretroviral therapy (ART) is in suppressing HIV and novel molecular and cellular strategies against HIV-1
in macrophages

Downloads

Download data is not yet available.

References

Iordanskiy S, Santos S, Bukrinsky M: Nature, nurture and HIV: the effect of producer cell on viral physiology. Virology. 2013, 443: 208-213. 10.1016/j.virol.2013.05.023.

PubMedCentralPubMedGoogle Scholar

Abbas W, Herbein G: T-cell signaling in HIV-1 infection. Open Virol J. 2013, 7: 57-71. 10.2174/1874357920130621001.

PubMedCentralPubMedGoogle Scholar

Ackerman AL, Cresswell P: Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol. 2004, 5: 678-684.

PubMedGoogle Scholar

Koppensteiner H, Brack-Werner R, Schindler M: Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology. 2012, 9: 82-10.1186/1742-4690-9-82.

PubMedCentralPubMedGoogle Scholar

Crowe SM, Mills J, Kirihara J, Boothman J, Marshall JA, McGrath MS: Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells. AIDS Res Hum Retroviruses. 1990, 6: 1031-1037.

PubMedGoogle Scholar

Crowe SM, Mills J, Elbeik T, Lifson JD, Kosek J, Marshall JA, Engleman EG, McGrath MS: Human immunodeficiency virus-infected monocyte-derived macrophages express surface gp120 and fuse with CD4 lymphoid cells in vitro: a possible mechanism of T lymphocyte depletion in vivo. Clin Immunol Immunopathol. 1992, 65: 143-151. 10.1016/0090-1229(92)90217-C.

PubMedGoogle Scholar

Groot F, Welsch S, Sattentau QJ: Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood. 2008, 111: 4660-4663. 10.1182/blood-2007-12-130070.

PubMedGoogle Scholar

Badley AD, Dockrell D, Simpson M, Schut R, Lynch DH, Leibson P, Paya CV: Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med. 1997, 185: 55-64. 10.1084/jem.185.1.55.

PubMedCentralPubMedGoogle Scholar

Herbein G, Mahlknecht U, Batliwalla F, Gregersen P, Pappas T, Butler J, O'Brien WA, Verdin E: Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature. 1998, 395: 189-194. 10.1038/26026.

PubMedGoogle Scholar

Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, Burke DS, Meltzer MS: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med. 1988, 167: 1428-1441. 10.1084/jem.167.4.1428.

PubMedGoogle Scholar

Carter CA, Ehrlich LS: Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol. 2008, 62: 425-443. 10.1146/annurev.micro.62.081307.162758.

PubMedGoogle Scholar

Kelly J, Beddall MH, Yu D, Iyer SR, Marsh JW, Wu Y: Human macrophages support persistent transcription from unintegrated HIV-1 DNA. Virology. 2008, 372: 300-312. 10.1016/j.virol.2007.11.007.

PubMedCentralPubMedGoogle Scholar

Gavegnano C, Schinazi RF: Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother. 2009, 20: 63-78. 10.3851/IMP1374.

PubMedCentralPubMedGoogle Scholar

Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998, 393: 648-659. 10.1038/31405.

PubMedGoogle Scholar

Herbein G, Varin A: The macrophage in HIV-1 infection: from activation to deactivation?. Retrovirology. 2010, 7: 33-10.1186/1742-4690-7-33.

PubMedCentralPubMedGoogle Scholar

Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, Manischewitz J, Golding H: Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med. 1997, 3: 1369-1375. 10.1038/nm1297-1369.

PubMedGoogle Scholar

Yi Y, Rana S, Turner JD, Gaddis N, Collman RG: CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol. 1998, 72: 772-777.

PubMedCentralPubMedGoogle Scholar

Abbas W, Herbein G: Plasma membrane signaling in HIV-1 infection. Biochim Biophys Acta. 2013, doi:10.1016/j.bbamem.2013.06.020

Google Scholar

Mougel M, Houzet L, Darlix JL: When is it time for reverse transcription to start and go?. Retrovirology. 2009, 6: 24-10.1186/1742-4690-6-24.

PubMedCentralPubMedGoogle Scholar

Herbein G, Gras G, Khan KA, Abbas W: Macrophage signaling in HIV-1 infection. Retrovirology. 2010, 7: 34-10.1186/1742-4690-7-34.

PubMedCentralPubMedGoogle Scholar

Gavegnano C, Kennedy EM, Kim B, Schinazi RF: The impact of macrophage nucleotide pools on HIV-1 reverse transcription, viral replication, and the development of novel antiviral agents. Mol Biol Int. 2012, 2012: 625983-

PubMedCentralPubMedGoogle Scholar

Schmidtmayerova H, Alfano M, Nuovo G, Bukrinsky M: Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol. 1998, 72: 4633-4642.

PubMedCentralPubMedGoogle Scholar

Furge LL, Guengerich FP: Analysis of nucleotide insertion and extension at 8-oxo-7,8-dihydroguanine by replicative T7 polymerase exo- and human immunodeficiency virus-1 reverse transcriptase using steady-state and pre-steady-state kinetics. Biochemistry. 1997, 36: 6475-6487. 10.1021/bi9627267.

PubMedGoogle Scholar

Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B: Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem. 2004, 279: 51545-51553. 10.1074/jbc.M408573200.

PubMedCentralPubMedGoogle Scholar

Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002, 418: 646-650. 10.1038/nature00939.

PubMedGoogle Scholar

Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008, 451: 425-430. 10.1038/nature06553.

PubMedGoogle Scholar

Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J: Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011, 474: 658-661. 10.1038/nature10195.

PubMedCentralPubMedGoogle Scholar

Vicenzi E, Poli G: Novel factors interfering with human immunodeficiency virus-type 1 replication in vivo and in vitro. Tissue Antigens. 2013, 81: 61-71. 10.1111/tan.12047.

PubMedGoogle Scholar

Goila-Gaur R, Strebel K: HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology. 2008, 5: 51-10.1186/1742-4690-5-51.

PubMedCentralPubMedGoogle Scholar

Sauter D, Kirchhoff F: Tetherin antagonism by primate lentiviral nef proteins. Curr HIV Res. 2011, 9: 514-523. 10.2174/157016211798842044.

PubMedGoogle Scholar

Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T: Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe. 2009, 6: 54-67. 10.1016/j.chom.2009.05.008.

PubMedCentralPubMedGoogle Scholar

Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F: SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012, 13: 223-228. 10.1038/ni.2236.

PubMedCentralPubMedGoogle Scholar

Liu L, Oliveira NM, Cheney KM, Pade C, Dreja H, Bergin AM, Borgdorff V, Beach DH, Bishop CL, Dittmar MT, McKnight A: A whole genome screen for HIV restriction factors. Retrovirology. 2011, 8: 94-10.1186/1742-4690-8-94.

PubMedCentralPubMedGoogle Scholar

Allouch A, David A, Amie SM, Lahouassa H, Chartier L, Margottin-Goguet F, Barré-Sinoussi F, Kim B, Sáez-Cirión A, Pancino G: p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci U S A. 2013, 110: E3997-E4006. 10.1073/pnas.1306719110.

PubMedCentralPubMedGoogle Scholar

Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M: Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A. 1992, 89: 6580-6584. 10.1073/pnas.89.14.6580.

PubMedCentralPubMedGoogle Scholar

Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M: Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A. 1993, 90: 6125-6129. 10.1073/pnas.90.13.6125.

PubMedCentralPubMedGoogle Scholar

Gallay P, Stitt V, Mundy C, Oettinger M, Trono D: Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import. J Virol. 1996, 70: 1027-1032.

PubMedCentralPubMedGoogle Scholar

Gallay P, Hope T, Chin D, Trono D: HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A. 1997, 94: 9825-9830. 10.1073/pnas.94.18.9825.

PubMedCentralPubMedGoogle Scholar

Nitahara-Kasahara Y, Kamata M, Yamamoto T, Zhang X, Miyamoto Y, Muneta K, Iijima S, Yoneda Y, Tsunetsugu-Yokota Y, Aida Y: Novel nuclear import of Vpr promoted by importin alpha is crucial for human immunodeficiency virus type 1 replication in macrophages. J Virol. 2007, 81: 5284-5293. 10.1128/JVI.01928-06.

PubMedCentralPubMedGoogle Scholar

Jacque JM, Stevenson M: The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity. Nature. 2006, 441: 641-645. 10.1038/nature04682.

PubMedGoogle Scholar

Kobiler O, Drayman N, Butin-Israeli V, Oppenheim A: Virus strategies for passing the nuclear envelope barrier. Nucleus. 2012, 3: 526-539. 10.4161/nucl.21979.

PubMedCentralPubMedGoogle Scholar

Shun MC, Daigle JE, Vandegraaff N, Engelman A: Wild-type levels of human immunodeficiency virus type 1 infectivity in the absence of cellular emerin protein. J Virol. 2007, 81: 166-172. 10.1128/JVI.01953-06.

PubMedCentralPubMedGoogle Scholar

Cobos-Jimenez V, Booiman T, Hamann J, Kootstra NA: Macrophages and HIV-1. Curr Opin HIV AIDS. 2011, 6: 385-390. 10.1097/COH.0b013e3283497203.

PubMedGoogle Scholar

Kilareski EM, Shah S, Nonnemacher MR, Wigdahl B: Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage. Retrovirology. 2009, 6: 118-10.1186/1742-4690-6-118.

PubMedCentralPubMedGoogle Scholar

Henderson AJ, Calame KL: CCAAT/enhancer binding protein (C/EBP) sites are required for HIV-1 replication in primary macrophages but not CD4(+) T cells. Proc Natl Acad Sci U S A. 1997, 94: 8714-8719. 10.1073/pnas.94.16.8714.

PubMedCentralPubMedGoogle Scholar

Frank I, Stoiber H, Godar S, Stockinger H, Steindl F, Katinger HW, Dierich MP: Acquisition of host cell-surface-derived molecules by HIV-1. AIDS. 1996, 10: 1611-1620. 10.1097/00002030-199612000-00004.

PubMedGoogle Scholar

Tan J, Sattentau QJ: The HIV-1-containing macrophage compartment: a perfect cellular niche?. Trends Microbiol. 2013, 21: 405-412. 10.1016/j.tim.2013.05.001.

PubMedGoogle Scholar

Orenstein JM, Meltzer MS, Phipps T, Gendelman HE: Cytoplasmic assembly and accumulation of human immunodeficiency virus types 1 and 2 in recombinant human colony-stimulating factor-1-treated human monocytes: an ultrastructural study. J Virol. 1988, 62: 2578-2586.

PubMedCentralPubMedGoogle Scholar

Raposo G, Moore M, Innes D, Leijendekker R, Leigh-Brown A, Benaroch P, Geuze H: Human macrophages accumulate HIV-1 particles in MHC II compartments. Traffic. 2002, 3: 718-729. 10.1034/j.1600-0854.2002.31004.x.

PubMedGoogle Scholar

Pelchen-Matthews A, Kramer B, Marsh M: Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol. 2003, 162: 443-455. 10.1083/jcb.200304008.

PubMedCentralPubMedGoogle Scholar

Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, Marsh M: In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol. 2007, 177: 329-341. 10.1083/jcb.200609050.

PubMedCentralPubMedGoogle Scholar

Kramer B, Pelchen-Matthews A, Deneka M, Garcia E, Piguet V, Marsh M: HIV interaction with endosomes in macrophages and dendritic cells. Blood Cells Mol Dis. 2005, 35: 136-142. 10.1016/j.bcmd.2005.06.006.

PubMedGoogle Scholar

Welsch S, Groot F, Krausslich HG, Keppler OT, Sattentau QJ: Architecture and regulation of the HIV-1 assembly and holding compartment in macrophages. J Virol. 2011, 85: 7922-7927. 10.1128/JVI.00834-11.

PubMedCentralPubMedGoogle Scholar

Welsch S, Keppler OT, Habermann A, Allespach I, Krijnse-Locker J, Krausslich HG: HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog. 2007, 3: e36-10.1371/journal.ppat.0030036.

PubMedCentralPubMedGoogle Scholar

Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, Ensoli B: Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol. 1992, 66: 7159-7167.

PubMedCentralPubMedGoogle Scholar

Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J, Chirmule N, McCloskey T, Pahwa S, Verdin E: Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science. 1997, 275: 1481-1485. 10.1126/science.275.5305.1481.

PubMedGoogle Scholar

Jeang KT, Xiao H, Rich EA: Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem. 1999, 274: 28837-28840. 10.1074/jbc.274.41.28837.

PubMedGoogle Scholar

Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC: Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 1993, 67: 277-287.

PubMedCentralPubMedGoogle Scholar

Huang L, Bosch I, Hofmann W, Sodroski J, Pardee AB: Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol. 1998, 72: 8952-8960.

PubMedCentralPubMedGoogle Scholar

Albini A, Benelli R, Giunciuglio D, Cai T, Mariani G, Ferrini S, Noonan DM: Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem. 1998, 273: 15895-15900. 10.1074/jbc.273.26.15895.

PubMedGoogle Scholar

Campbell GR, Loret EP: What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?. Retrovirology. 2009, 6: 50-10.1186/1742-4690-6-50.

PubMedCentralPubMedGoogle Scholar

Chen P, Mayne M, Power C, Nath A: The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases. J Biol Chem. 1997, 272: 22385-22388. 10.1074/jbc.272.36.22385.

PubMedGoogle Scholar

Mayne M, Holden CP, Nath A, Geiger JD: Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-alpha production in human macrophages. J Immunol. 2000, 164: 6538-6542.

PubMedGoogle Scholar

Nath A: Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis. 2002, 186 (Suppl 2): S193-S198.

PubMedGoogle Scholar

Subbramanian RA, Kessous-Elbaz A, Lodge R, Forget J, Yao XJ, Bergeron D, Cohen EA: Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med. 1998, 187: 1103-1111. 10.1084/jem.187.7.1103.

PubMedCentralPubMedGoogle Scholar

Jacquot G, Le RE, David A, Mazzolini J, Bouchet J, Bouaziz S, Niedergang F, Pancino G, Benichou S: Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology. 2007, 4: 84-10.1186/1742-4690-4-84.

PubMedCentralPubMedGoogle Scholar

Bukrinsky M, Adzhubei A: Viral protein R of HIV-1. Rev Med Virol. 1999, 9: 39-49. 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3.

PubMedGoogle Scholar

Varin A, Decrion AZ, Sabbah E, Quivy V, Sire J, Van Lint C, Roques BP, Aggarwal BB, Herbein G: Synthetic Vpr protein activates activator protein-1, c-Jun N-terminal kinase, and NF-kappaB and stimulates HIV-1 transcription in promonocytic cells and primary macrophages. J Biol Chem. 2005, 280: 42557-42567. 10.1074/jbc.M502211200.

PubMedGoogle Scholar

Eckstein DA, Sherman MP, Penn ML, Chin PS, De Noronha CM, Greene WC, Goldsmith MA: HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med. 2001, 194: 1407-1419. 10.1084/jem.194.10.1407.

PubMedCentralPubMedGoogle Scholar

Vazquez N, Greenwell-Wild T, Marinos NJ, Swaim WD, Nares S, Ott DE, Schubert U, Henklein P, Orenstein JM, Sporn MB, Wahl SM: Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. J Virol. 2005, 79: 4479-4491. 10.1128/JVI.79.7.4479-4491.2005.

PubMedCentralPubMedGoogle Scholar

Das SR, Jameel S: Biology of the HIV Nef protein. Indian J Med Res. 2005, 121: 315-332.

PubMedGoogle Scholar

Lamers SL, Fogel GB, Singer EJ, Salemi M, Nolan DJ, Huysentruyt LC, McGrath MS: HIV-1 Nef in macrophage-mediated disease pathogenesis. Int Rev Immunol. 2012, 31: 432-450. 10.3109/08830185.2012.737073.

PubMedCentralPubMedGoogle Scholar

Lama J, Mangasarian A, Trono D: Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol. 1999, 9: 622-631. 10.1016/S0960-9822(99)80284-X.

PubMedGoogle Scholar

Foster JL, Garcia JV: HIV-1 Nef: at the crossroads. Retrovirology. 2008, 5: 84-10.1186/1742-4690-5-84.

PubMedCentralPubMedGoogle Scholar

Tachado SD, Li X, Swan K, Patel N, Koziel H: Constitutive activation of phosphatidylinositol 3-kinase signaling pathway down-regulates TLR4-mediated tumor necrosis factor-alpha release in alveolar macrophages from asymptomatic HIV-positive persons in vitro. J Biol Chem. 2008, 283: 33191-33198. 10.1074/jbc.M805067200.

PubMedCentralPubMedGoogle Scholar

Lama J: The physiological relevance of CD4 receptor down-modulation during HIV infection. Curr HIV Res. 2003, 1: 167-184. 10.2174/1570162033485276.

PubMedGoogle Scholar

Mangino G, Percario ZA, Fiorucci G, Vaccari G, Acconcia F, Chiarabelli C, Leone S, Noto A, Horenkamp FA, Manrique S, Romeo G, Polticelli F, Geyer M, Affabris E: HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TNF alpha receptor associated factor 2. PLoS One. 2011, 6: e22982-10.1371/journal.pone.0022982.

PubMedCentralPubMedGoogle Scholar

Mangino G, Percario ZA, Fiorucci G, Vaccari G, Manrique S, Romeo G, Federico M, Geyer M, Affabris E: In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-activated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the release of beta interferon. J Virol. 2007, 81: 2777-2791. 10.1128/JVI.01640-06.

PubMedCentralPubMedGoogle Scholar

Khan KA, Abbas W, Varin A, Kumar A, Di Martino V, Dichamp I, Herbein G: HIV-1 Nef interacts with HCV core, recruits TRAF2, TRAF5 and TRAF6, and stimulates HIV-1 replication in macrophages. J Innate Immun. 2013, 5: 639-656. 10.1159/000350517.

PubMedGoogle Scholar

Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, Baba TW, Ruprecht RM, Kupfer A: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med. 1995, 1: 129-134. 10.1038/nm0295-129.

PubMedGoogle Scholar

Swingler S, Brichacek B, Jacque JM, Ulich C, Zhou J, Stevenson M: HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature. 2003, 424: 213-219. 10.1038/nature01749.

PubMedGoogle Scholar

Oyaizu N, Adachi Y, Hashimoto F, McCloskey TW, Hosaka N, Kayagaki N, Yagita H, Pahwa S: Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J Immunol. 1997, 158: 2456-2463.

PubMedGoogle Scholar

Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC: HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature. 2001, 410: 834-838. 10.1038/35071111.

PubMedGoogle Scholar

Mahlknecht U, Deng C, Lu MC, Greenough TC, Sullivan JL, O’Brien WA, Herbein G: Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence. J Immunol. 2000, 165: 6437-6446.

PubMedGoogle Scholar

Zhang M, Li X, Pang X, Ding L, Wood O, Clouse K, Hewlett I, Dayton AI: Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat. J Biomed Sci. 2001, 8: 290-296. 10.1007/BF02256603.

PubMedGoogle Scholar

Yang Y, Tikhonov I, Ruckwardt TJ, Djavani M, Zapata JC, Pauza CD, Salvato MS: Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol. 2003, 77: 6700-6708. 10.1128/JVI.77.12.6700-6708.2003.

PubMedCentralPubMedGoogle Scholar

Lin RH, Hwang YW, Yang BC, Lin CS: TNF receptor-2-triggered apoptosis is associated with the down-regulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. J Immunol. 1997, 158: 598-603.

PubMedGoogle Scholar

Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994, 68: 4650-4655.

PubMedCentralPubMedGoogle Scholar

Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science. 1998, 279: 2103-2106. 10.1126/science.279.5359.2103.

PubMedGoogle Scholar

Pozzi LA, Maciaszek JW, Rock KL: Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol. 2005, 175: 2071-2081.

PubMedGoogle Scholar

Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 1998, 391: 397-401. 10.1038/34929.

PubMedGoogle Scholar

Fujiwara M, Takiguchi M: HIV-1-specific CTLs effectively suppress replication of HIV-1 in HIV-1-infected macrophages. Blood. 2007, 109: 4832-4838. 10.1182/blood-2006-07-037481.

PubMedGoogle Scholar

Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000, 164: 6166-6173.

PubMedGoogle Scholar

Cassol E, Cassetta L, Rizzi C, Alfano M, Poli G: M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol. 2009, 182: 6237-6246. 10.4049/jimmunol.0803447.

PubMedGoogle Scholar

Badley AD, Pilon AA, Landay A, Lynch DH: Mechanisms of HIV-associated lymphocyte apoptosis. Blood. 2000, 96: 2951-2964.

PubMedGoogle Scholar

Badley AD, Sainski A, Wightman F, Lewin SR: Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis. 2013, 4: e718-10.1038/cddis.2013.248.

PubMedCentralPubMedGoogle Scholar

Schnepple DJ, Shepard B, Bren GD, Cummins NW, Natesampillai S, Trushin S, Algeciras-Schimnich A, Meng XW, Sainski AM, Rizza SA, Kaufmann SH, Badley AD: Isolation of a TRAIL antagonist from the serum of HIV-infected patients. J Biol Chem. 2011, 286: 35742-35754. 10.1074/jbc.M111.274639.

PubMedCentralPubMedGoogle Scholar

Sainski AM, Natesampillai S, Cummins NW, Bren GD, Taylor J, Saenz DT, Poeschla EM, Badley AD: The HIV-1-specific protein Casp8p41 induces death of infected cells through Bax/Bak. J Virol. 2011, 85: 7965-7975. 10.1128/JVI.02515-10.

PubMedCentralPubMedGoogle Scholar

Cummins NW, Badley AD: Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV. Cell Mol Life Sci. 2013, 70: 3355-3363. 10.1007/s00018-012-1239-3.

PubMedCentralPubMedGoogle Scholar

Swingler S, Mann AM, Zhou J, Swingler C, Stevenson M: Apoptotic killing of HIV-1-infected macrophages is subverted by the viral envelope glycoprotein. PLoS Pathog. 2007, 3: 1281-1290.

PubMedGoogle Scholar

Busca A, Saxena M, Kumar A: Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis. J Biol Chem. 2012, 287: 15118-15133. 10.1074/jbc.M111.312660.

PubMedCentralPubMedGoogle Scholar

Pomerantz RJ, Horn DL: Twenty years of therapy for HIV-1 infection. Nat Med. 2003, 9: 867-873. 10.1038/nm0703-867.

PubMedGoogle Scholar

Anderson AM, Lennox JL: Antiretroviral therapy: when to start and which drugs to use. Curr Infect Dis Rep. 2008, 10: 332-339. 10.1007/s11908-008-0053-4.

PubMedGoogle Scholar

Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998, 338: 853-860. 10.1056/NEJM199803263381301.

PubMedGoogle Scholar

Abbas W, Herbein G: Molecular understanding of HIV-1 latency. Adv Virol. 2012, 2012: 574967-

PubMedCentralPubMedGoogle Scholar

Perno CF, Svicher V, Schols D, Pollicita M, Balzarini J, Aquaro S: Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Res. 2006, 71: 293-300. 10.1016/j.antiviral.2006.05.015.

PubMedGoogle Scholar

Aquaro S, Calio R, Balestra E, Bagnarelli P, Cenci A, Bertoli A, Tavazzi B, Di Pierro D, Francesconi M, Abdelahad D, Perno CF: Clinical implications of HIV dynamics and drug resistance in macrophages. J Biol Regul Homeost Agents. 1998, 12: 23-27.

PubMedGoogle Scholar

Aquaro S, Svicher V, Schols D, Pollicita M, Antinori A, Balzarini J, Perno CF: Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies. J Leukoc Biol. 2006, 80: 1103-1110.

PubMedGoogle Scholar

Haworth SJ, Christofalo B, Anderson RD, Dunkle LM: A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults. J Acquir Immune Defic Syndr Hum Retrovirol. 1998, 17: 235-238. 10.1097/00042560-199803010-00008.

PubMedGoogle Scholar

Limoges J, Persidsky Y, Poluektova L, Rasmussen J, Ratanasuwan W, Zelivyanskaya M, McClernon DR, Lanier ER, Gendelman HE: Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology. 2000, 54: 379-389. 10.1212/WNL.54.2.379.

PubMedGoogle Scholar

Aquaro S, Svicher V, Ceccherini-Silberstein F, Cenci A, Marcuccilli F, Giannella S, Marcon L, Caliò R, Balzarini J, Perno CF: Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages. J Antimicrob Chemother. 2005, 55: 872-878. 10.1093/jac/dki104.

PubMedGoogle Scholar

Chariot P, Monnet I, Gherardi R: Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy. Ann Neurol. 1993, 34: 561-565. 10.1002/ana.410340409.

PubMedGoogle Scholar

Viora M, Di GG, Rivabene R, Malorni W, Fattorossi A: Interference with cell cycle progression and induction of apoptosis by dideoxynucleoside analogs. Int J Immunopharmacol. 1997, 19: 311-321. 10.1016/S0192-0561(97)00041-6.

PubMedGoogle Scholar

Pilon AA, Lum JJ, Sanchez-Dardon J, Phenix BN, Douglas R, Badley AD: Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2002, 46: 2687-2691. 10.1128/AAC.46.8.2687-2691.2002.

PubMedCentralPubMedGoogle Scholar

Siliciano RF, Greene WC: HIV latency. Cold Spring Harb Perspect Med. 2011, 1: a007096-

PubMedCentralPubMedGoogle Scholar

Van Lint C, Bouchat S, Marcello A: HIV-1 transcription and latency: an update. Retrovirology. 2013, 10: 67-10.1186/1742-4690-10-67.

PubMedCentralPubMedGoogle Scholar

Scopelliti F, Pollicita M, Ceccherini-Silberstein F, Di SF, Surdo M, Aquaro S, Perno CF: Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. Antiviral Res. 2011, 92: 255-261. 10.1016/j.antiviral.2011.08.008.

PubMedGoogle Scholar

Marsden MD, Avancena P, Kitchen CM, Hubbard T, Zack JA: Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother. 2011, 55: 3696-3702. 10.1128/AAC.00566-11.

PubMedCentralPubMedGoogle Scholar

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, Lazzarin A, Clementi M: In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. J Antimicrob Chemother. 2013, 68: 2525-2532. 10.1093/jac/dkt220.

PubMedGoogle Scholar

Perno CF, Aquaro S, Rosenwirth B, Balestra E, Peichl P, Billich A, Villani N, Caliò R: In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukoc Biol. 1994, 56: 381-386.

PubMedGoogle Scholar

Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Calio R, Yarchoan R: Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis. 1998, 178: 413-422. 10.1086/515642.

PubMedGoogle Scholar

Yi Y, Loftin L, Wang L, Ratcliffe SJ, Isaacman-Beck J, Collman RG: Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection. J Acquir Immune Defic Syndr. 2008, 47: 285-292. 10.1097/QAI.0b013e31816520f6.

PubMedCentralPubMedGoogle Scholar

Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, Webster R, Armour D, Price D, Stammen B, Wood A, Perros M: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005, 49: 4721-4732. 10.1128/AAC.49.11.4721-4732.2005.

PubMedCentralPubMedGoogle Scholar

Moore JP, Kuritzkes DR: A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS. 2009, 4: 118-124. 10.1097/COH.0b013e3283223d46.

PubMedCentralPubMedGoogle Scholar

Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP: Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci U S A. 2009, 106: 5318-5323. 10.1073/pnas.0811713106.

PubMedCentralPubMedGoogle Scholar

Balzarini J: Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?. Antivir Chem Chemother. 2007, 18: 1-11.

PubMedGoogle Scholar

Pollicita M, Schols D, Aquaro S, Peumans WJ, Van Damme EJ, Perno CF, Balzarini J: Carbohydrate-binding agents (CBAs) inhibit HIV-1 infection in human primary monocyte-derived macrophages (MDMs) and efficiently prevent MDM-directed viral capture and subsequent transmission to CD4+ T lymphocytes. Virology. 2008, 370: 382-391. 10.1016/j.virol.2007.08.033.

PubMedGoogle Scholar

Balzarini J, Van HY, Vermeire K, Vanham G, Schols D: Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol. 2007, 71: 3-11.

PubMedGoogle Scholar

Hoorelbeke B, Xue J, LiWang PJ, Balzarini J: Role of the carbohydrate-binding sites of griffithsin in the prevention of DC-SIGN-mediated capture and transmission of HIV-1. PLoS One. 2013, 8: e64132-10.1371/journal.pone.0064132.

PubMedCentralPubMedGoogle Scholar

El-Deiry WS: Akt takes centre stage in cell-cycle deregulation. Nat Cell Biol. 2001, 3: E71-E73. 10.1038/35060148.

PubMedGoogle Scholar

Morgensztern D, McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005, 16: 797-803. 10.1097/01.cad.0000173476.67239.3b.

PubMedGoogle Scholar

Knowling M, Blackstein M, Tozer R, Bramwell V, Dancey J, Dore N, Matthews S, Eisenhauer E: A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs. 2006, 24: 435-439. 10.1007/s10637-006-6406-7.

PubMedGoogle Scholar

Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, Dewhurst S, Kim B: Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology. 2008, 5: 11-10.1186/1742-4690-5-11.

PubMedCentralPubMedGoogle Scholar

Leonard JN, Schaffer DV: Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther. 2006, 13: 532-540. 10.1038/sj.gt.3302645.

PubMedGoogle Scholar

Song E, Lee SK, Dykxhoorn DM, Novina C, Zhang D, Crawford K, Cerny J, Sharp PA, Lieberman J, Manjunath N, Shankar P: Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol. 2003, 77: 7174-7181. 10.1128/JVI.77.13.7174-7181.2003.

PubMedCentralPubMedGoogle Scholar

Tyagi A, Ahmed F, Thakur N, Sharma A, Raghava GP, Kumar M: HIVsirDB: a database of HIV inhibiting siRNAs. PLoS One. 2011, 6: e25917-10.1371/journal.pone.0025917.

PubMedCentralPubMedGoogle Scholar

Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins JI, Mellors J, Moreno S, O'Doherty U, Palmer S, Penicaud MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M: Towards an HIV cure: a global scientific strategy. Nat Rev Immunol. 2012, 12: 607-614. 10.1038/nri3262.

PubMedGoogle Scholar

Chun TW, Davey RT, Engel D, Lane HC, Fauci AS: Re-emergence of HIV after stopping therapy. Nature. 1999, 401: 874-875. 10.1038/44755.

PubMedGoogle Scholar

Jacobson MA, Hardy D, Connick E, Watson J, DeBruin M: Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100–500 CD4 cells/microL. J Infect Dis. 2000, 182: 1070-1076. 10.1086/315819.

PubMedGoogle Scholar

Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM: Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS. 2002, 16: 1103-1111. 10.1097/00002030-200205240-00003.

PubMedGoogle Scholar

Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelievre JD, Boué F, Molina JM, Rouzioux C, Avettand-Fénoêl V, Croughs T, Beq S, Thiébaut R, Chêne G, Morre M, Delfraissy JF: Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest. 2009, 119: 997-1007.

PubMedCentralPubMedGoogle Scholar

Seder RA, Grabstein KH, Berzofsky JA, McDyer JF: Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J Exp Med. 1995, 182: 1067-1077. 10.1084/jem.182.4.1067.

PubMedGoogle Scholar

Mueller YM, Do DH, Altork SR, Artlett CM, Gracely EJ, Katsetos CD, Legido A, Villinger F, Altman JD, Brown CR, Lewis MG, Katsikis PD: IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses. J Immunol. 2008, 180: 350-360. 10.4049/jimmunol.180.1.350.

PubMedCentralPubMedGoogle Scholar

Pallikkuth S, Rogers K, Villinger F, Dosterii M, Vaccari M, Franchini G, Pahwa R, Pahwa S: Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine. 2011, 29: 9229-9238. 10.1016/j.vaccine.2011.09.118.

PubMedCentralPubMedGoogle Scholar

Vignali DA, Kuchroo VK: IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012, 13: 722-728. 10.1038/ni.2366.

PubMedCentralPubMedGoogle Scholar

Hunter CA: New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol. 2005, 5: 521-531. 10.1038/nri1648.

PubMedGoogle Scholar

Chen Q, Swaminathan S, Yang D, Dai L, Sui H, Yang J, Hornung RL, Wang Y, Huang da W, Hu X, Lempicki RA, Imamichi T: Interleukin-27 is a potent inhibitor of cis HIV-1 replication in monocyte-derived dendritic cells via a type I interferon-independent pathway. PLoS One. 2013, 8: e59194-10.1371/journal.pone.0059194.

PubMedCentralPubMedGoogle Scholar

Dai L, Lidie KB, Chen Q, Adelsberger JW, Zheng X, Huang D, Yang J, Lempicki RA, Rehman T, Dewar RL, Wang Y, Hornung RL, Canizales KA, Lockett SJ, Lane HC, Imamichi T: IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. J Exp Med. 2013, 210: 517-534. 10.1084/jem.20120572.

PubMedCentralPubMedGoogle Scholar

Park K: Nanotechnology: what it can do for drug delivery. J Control Release. 2007, 120: 1-3. 10.1016/j.jconrel.2007.05.003.

PubMedCentralPubMedGoogle Scholar

Langer R: Drug delivery. Drugs on target. Science. 2001, 293: 58-59. 10.1126/science.1063273.

PubMedGoogle Scholar

Wan L, Pooyan S, Hu P, Leibowitz MJ, Stein S, Sinko PJ: Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm Res. 2007, 24: 2110-2119. 10.1007/s11095-007-9402-5.

PubMedCentralPubMedGoogle Scholar

Vandamme AM, Van VK, De CE: Anti-human immunodeficiency virus drug combination strategies. Antivir Chem Chemother. 1998, 9: 187-203.

PubMedGoogle Scholar

Clifford DB: HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med. 2008, 16: 94-98.

PubMedGoogle Scholar

Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group: HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010, 75: 2087-2096. 10.1212/WNL.0b013e318200d727.

PubMedCentralPubMedGoogle Scholar

Zink MC, Brice AK, Kelly KM, Queen SE, Gama L, Li M, Adams RJ, Bartizal C, Varrone J, Rabi SA, Graham DR, Tarwater PM, Mankowski JL, Clements JE: Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis. 2010, 202: 161-170. 10.1086/653213.

PubMedCentralPubMedGoogle Scholar

Kim HJ, Martemyanov KA, Thayer SA: Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci. 2008, 28: 12604-12613. 10.1523/JNEUROSCI.2958-08.2008.

PubMedCentralPubMedGoogle Scholar

Lu SM, Tremblay ME, King IL, Qi J, Reynolds HM, Marker DF, Varrone JJ, Majewska AK, Dewhurst S, Gelbard HA: HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. PLoS One. 2011, 6: e23915-10.1371/journal.pone.0023915.

PubMedCentralPubMedGoogle Scholar

Bagashev A, Sawaya BE: Roles and functions of HIV-1 Tat protein in the CNS: an overview. Virol J. 2013, 10: 358-10.1186/1743-422X-10-358.

PubMedCentralPubMedGoogle Scholar

Rodriguez-Franco EJ, Cantres-Rosario YM, Plaud-Valentin M, Romeu R, Rodriguez Y, Skolasky R, Meléndez V, Cadilla CL, Melendez LM: Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis. PLoS One. 2012, 7: e36571-10.1371/journal.pone.0036571.

PubMedCentralPubMedGoogle Scholar

Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF: In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995, 1: 1284-1290. 10.1038/nm1295-1284.

PubMedGoogle Scholar

Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997, 387: 183-188. 10.1038/387183a0.

PubMedGoogle Scholar

Eisele E, Siliciano RF: Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity. 2012, 37: 377-388. 10.1016/j.immuni.2012.08.010.

PubMedCentralPubMedGoogle Scholar

Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S, Hwangbo Y, Mullins JI, Corey L: Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol. 2002, 76: 707-716. 10.1128/JVI.76.2.707-716.2002.

PubMedCentralPubMedGoogle Scholar

Alexaki A, Wigdahl B: HIV-1 infection of bone marrow hematopoietic progenitor cells and their role in trafficking and viral dissemination. PLoS Pathog. 2008, 4: e1000215-10.1371/journal.ppat.1000215.

PubMedCentralPubMedGoogle Scholar

Redel L, Le Douce V, Cherrier T, Marban C, Janossy A, Aunis D, Van Lint C, Rohr O, Schwartz C: HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes. J Leukoc Biol. 2010, 87: 575-588.

PubMedGoogle Scholar

McElrath MJ, Steinman RM, Cohn ZA: Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J Clin Invest. 1991, 87: 27-30. 10.1172/JCI114981.

PubMedCentralPubMedGoogle Scholar

Caselli E, Galvan M, Cassai E, Caruso A, Sighinolfi L, Di LD: Human herpesvirus 8 enhances human immunodeficiency virus replication in acutely infected cells and induces reactivation in latently infected cells. Blood. 2005, 106: 2790-2797. 10.1182/blood-2005-04-1390.

PubMedGoogle Scholar

Jones J, Kosloff BR, Benveniste EN, Shaw GM, Kutsch O: Amphotericin-B-mediated reactivation of latent HIV-1 infection. Virology. 2005, 331: 106-116. 10.1016/j.virol.2004.10.013.

PubMedGoogle Scholar

Gonzalez OA, Li M, Ebersole JL, Huang CB: HIV-1 reactivation induced by the periodontal pathogens Fusobacterium nucleatum and Porphyromonas gingivalis involves Toll-like receptor 2 [corrected] and 9 activation in monocytes/macrophages. Clin Vaccine Immunol. 2010, 17: 1417-1427. 10.1128/CVI.00009-10.

PubMedCentralPubMedGoogle Scholar

Huang CB, Alimova YV, Strange S, Ebersole JL: Polybacterial challenge enhances HIV reactivation in latently infected macrophages and dendritic cells. Immunology. 2011, 132: 401-409. 10.1111/j.1365-2567.2010.03375.x.

PubMedCentralPubMedGoogle Scholar

Le Douce V, Herbein G, Rohr O, Schwartz C: Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology. 2010, 7: 32-10.1186/1742-4690-7-32.

PubMedCentralPubMedGoogle Scholar

Marban C, Redel L, Suzanne S, Van Lint C, Lecestre D, Chasserot-Golaz S, Leid M, Aunis D, Schaeffer E, Rohr O: COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. Nucleic Acids Res. 2005, 33: 2318-2331. 10.1093/nar/gki529.

PubMedCentralPubMedGoogle Scholar

Kumar A, Abbas W, Herbein G: TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?. Mediators Inflamm. 2013, 2013: 484378-

PubMedCentralPubMedGoogle Scholar

Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005, 366: 549-555. 10.1016/S0140-6736(05)67098-5.

PubMedCentralPubMedGoogle Scholar

Siliciano JD, Lai J, Callender M, Pitt E, Zhang H, Margolick JB, Gallant JE, Cofrancesco J Jr, Moore RD, Gange SJ, Siliciano RF: Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis. 2007, 195: 833-836. 10.1086/511823.

PubMedGoogle Scholar

Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, Goujard C, Pallier C, Delfraissy JF, Lambotte O, ANRS EP39 study: Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS. 2008, 22: 1125-1129. 10.1097/QAD.0b013e3282fd6ddc.

PubMedGoogle Scholar

Savarino A, Mai A, Norelli S, El DS, Valente S, Rotili D, Altucci L, Palamara AT, Garaci E: “Shock and kill” effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology. 2009, 6: 52-10.1186/1742-4690-6-52.

PubMedCentralPubMedGoogle Scholar

Matalon S, Palmer BE, Nold MF, Furlan A, Kassu A, Fossati G, Mascagni P, Dinarello CA: The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr. 2010, 54: 1-9.

PubMedCentralPubMedGoogle Scholar

Furlan A, Monzani V, Reznikov LL, Leoni F, Fossati G, Modena D, Mascagni P, Dinarello CA: Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol Med. 2011, 17: 353-362.

PubMedCentralPubMedGoogle Scholar

Dallas S, Miller DS, Bendayan R: Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol Rev. 2006, 58: 140-161. 10.1124/pr.58.2.3.

PubMedGoogle Scholar

Shikuma CM, Nakamoto B, Shiramizu B, Liang CY, DeGruttola V, Bennett K, Paul R, Kallianpur K, Chow D, Gavegnano C, Hurwitz SJ, Schinazi RF, Valcour VG: Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012, 17: 1233-1242. 10.3851/IMP2411.

PubMedCentralPubMedGoogle Scholar

Published
2019-01-31
Section
Review